Di halaman ini
ABBV AbbVie Inc. Common Stock
NYSE · Biotechnology · Lihat di SEC EDGAR ↗ 10-K/10-Q Agu 3, 2026
$285,64
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$190,75rendah 52m
$291,40tinggi 52m
P/E (TTM)
80.7
EPS (TTM)
$3.54
Pendapatan (TTM)
$64.39B
lencana Anda
Rentang 52M
$191–$291
Peringkat Analis
BUY
Target Harga
$283
P/E
80.7
ROE
-206.3%
Margin Laba Bersih
9.8%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
ABBV Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$285.64
P/E (TTM)
80.7
EPS (TTM)
$3.54
Pendapatan (TTM)
$64.39B
ROE (TTM)
-206.3%
D/E Utang/Ekuitas (MRQ)
-0.0
Rentang 52M
$191–$291
ABBV Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Tentang AbbVie Inc. Common Stock Tinjauan perusahaan dari Wikipedia
AbbVie adalah sebuah perusahaan biofarmasi publik asal Amerika yang didirikan pada tahun 2013. Perusahaan ini berasal dari pemisahan Abbott Laboratories.
Sejarah
Pada tanggal 19 Oktober 2011, Abbott Laboratories mengumumkan rencana untuk membagi organisasinya menjadi dua perusahaan publik. Abbott Laboratories akan fokus pada produk terdiversifikasi, seperti alat kesehatan, peralatan diagnostik, dan produk nutrisi, sementara AbbVie akan beroperasi sebagai sebuah produsen farmasi berbasis riset. Pemisahan tersebut akhirnya mulai berlaku pada tanggal 1 Januari 2013, dan AbbVie pun resmi melantai di Bursa Saham New York (ABBV) keesokan harinya.
Menurut Miles White, CEO pada saat itu, tujuan pemisahan adalah untuk memungkinkan pasar menilai dua perusahaan tersebut secara terpisah. Sejumlah investor khawatir bahwa pemisahan tersebut dilakukan untuk melindungi nilai bisnis alat kesehatan dari berkurangnya nilai divisi obat akibat paten Humira yang akan kedaluwarsa, padahal Humira menyumbang sekitar separuh dari pendapatan divisi obat.
Hingga bulan Desember 2015, perusahaan ini mempekerjakan 28.000 orang di seluruh dunia, dan menyediakan produk untuk individu di lebih dari 170 negara.
Pada bulan Maret 2020, saat pandemi COVID-19 berkembang menjadi sebuah krisis internasional, pemerintah Israel mengumumkan bahwa mereka akan menekan AbbVie untuk melisensikan patennya atas Kaletra, nama merek dari lopinavir/ritonavir, sebuah medikasi kombinasi dosis tetap untuk mengobati dan mencegah HIV/AIDS yang diduga memiliki sejumlah kecocokan untuk melawan COVID-19. Sebagai tanggapan, AbbVie mengumumkan bahwa mereka akan berhenti menegakkan paten atas semua obatnya.
Akuisisi
Pada bulan Januari 2014, perusahaan ini resmi mengakuisisi ImmuVen. Pada tanggal 3 September 2014, AbbVie dan Infinity Pharmaceuticals mengumumkan bahwa mereka telah menjalin kolaborasi global untuk mengembangkan dan mengkomersialisasikan duvelisib, penghambat PI3K buatan Infinity untuk mengobati pasien kanker. Pada hari yang sama, AbbVie dan Calico mengumumkan bahwa mereka telah menjalin kolaborasi riset dan pengembangan untuk menciptakan, mengembangkan, dan membawa terapi baru untuk para penderita penyakit yang terkait dengan usia, seperti neurodegenerasi dan kanker. California Life Company, beroperasi dengan nama Calico, adalah anak usaha Alphabet Inc. yang fokus pada penyakit yang terkait dengan usia dan penuaan. Calico dipimpin oleh mantan chairman dan CEO Genentech, Arthur D. Levinson serta mantan EVP dan direktur medis Genentech, Hal V. Barron.
Pada bulan Oktober 2014, setelah lama bernegosiasi, AbbVie menghentikan upayanya untuk mengakuisisi Shire, yang andai terjadi akan menjadi salah satu kesepakatan akuisisi terbesar pada tahun 2014, dan menjadi salah satu inversi pajak terbesar dalam sejarah, karena adanya perubahan peraturan perpajakan dari Departemen Keuangan Amerika Serikat membuat AbbVie harus membayar biaya perpisahan sebesar $1,6 miliar.
Pada tanggal 4 Maret 2015, AbbVie mengumumkan bahwa mereka telah setuju untuk mengakuisisi perusahaan onkologi Pharmacyclics dan obat kanker darahnya, ibrutinib. AstraZeneca sebelumnya juga telah mengajukan tawaran untuk mengakuisisi Pharmacyclics. Pada akuisisi tersebut, AbbVie setuju untuk membayar $261,25 per lembar saham Pharmacyclics, dan akuisisi senilai $21 miliar tersebut akhirnya selesai pada tanggal 26 Mei 2015. Nama Pharmacyclics tetap dipertahankan, dan beroperasi sebagai anak usaha dari AbbVie. Pada tanggal 3 Juni 2015, AbbVie dan Halozyme Therapeutics mengumumkan bahwa mereka telah menjalin kolaborasi global dan perjanjian lisensi untuk mengembangkan dan mengkomersialisasikan produk yang menggabungkan obat buatan AbbVie dan teknologi pengantaran obat ENHANZE buatan Halozyme. Kolaborasi tersebut akhirnya dihentikan pada bulan November 2016.
Pada tanggal 28 April 2016, perusahaan ini mengumumkan bahwa mereka akan mengakuisisi Stemcentrx dengan harga $9,8 miliar. Keesokan harinya, perusahaan ini mengumumkan perluasan kesepakatan fibrosis kistik dengan Galapagos, yang berpotensi menggandakan pembayaran bertahap menjadi $600 juta.
Pada tanggal 25 Juni 2019, AbbVie mengumumkan bahwa mereka akan mengakuisisi Allergan plc asal Irlandia dengan harga $63 miliar. Namun transaksi tersebut tidak akan dijalankan sebagai sebuah inversi pajak, dan pasca transaksi tersebut, AbbVie (dan anak usahanya) akan tetap berdomisili di Amerika Serikat untuk tujuan perpajakan; Akuisisi AbbVie terhadap Allergan plc akhirnya disetujui oleh Federal Trade Commission pada tanggal 4 September 2020 dengan beberapa syarat. Pada bulan Juli 2019, perusahaan ini mengumumkan bahwa mereka akan mengakuisisi Mavupharma, untuk memperkuat portofolio obat kankernya.
Sejarah akuisisi
Kolaborasi
Pada tanggal 10 Februari 2016, AbbVie dan Synlogic asal Cambridge, Massachusetts mengumumkan sebuah kolaborasi riset dan pengembangan tahun jamak. Synlogic adalah sebuah perusahaan biologi sintetis yang didirikan berdasarkan riset dari James Collins dan Tim Lu di MIT. Sebagai bagian dari kolaborasi tersebut, AbbVie mendapat hak atas teknologi berbasis probiotik buatan Synlogic untuk mengobati penyakit radang usus. Tim riset akan fokus pada penyakit Crohn dan kolitis ulseratif. Pada bulan April 2016, perusahaan ini resmi bermitra dengan Universitas Chicago untuk menginvestigasi sejumlah bidang onkologi, yakni kanker payudara, paru-paru, prostat, usus besar, dan darah. Pada bulan yang sama, perusahaan ini mengumumkan bahwa mereka akan ikut mengkomersialisasikan imunoterapi praklinis ARGX-115 buatan Argenx. ARGX-115 adalah imunoterapi pertama di kelasnya yang menargetkan GARP (glycoprotein A repetitions predominant), sebuah protein membran yang dipercaya dapat menambah dampak imunosupresif dari sel T. Perusahaan ini juga mengumumkan kesepakatan untuk ikut mengembangkan / mengkomersialisasikan setidaknya satu konjugat buatan CytomX Probody untuk melawan CD71 (reseptor transferin 1).
Referensi
Pranala luar
Media terkait AbbVie Inc. di Wikimedia Commons
Data bisnis AbbVie:
Sumber: Wikipedia, CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan57.000
negaraUS
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$61.16B2016-12-31 → 2025-12-31
EPS$2.362016-12-31 → 2025-12-31
Arus Kas Bebas$17.82B2016-12-31 → 2025-12-31
Margin bersih9.8%2016-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | ABBV | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | 80.7rata-rata 5T ≈54.7 | ≈54.7 | 25.7 | Terlalu mahal |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | ABBV | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | 26.2%rata-rata 5T ≈25.5% | ≈25.5% | 30.1% | Tingkat teratas | |
| EBITDA Margin (Margin EBITDA) | 24.6%rata-rata 5T ≈25.5% | ≈25.5% | 30.1% | Tingkat teratas | |
| Margin Sebelum Pajak (TTM) | 13.5%rata-rata 5T ≈15.0% | ≈15.0% | 25.2% | Sejajar | |
| Margin Laba Bersih (TTM) | 9.8%rata-rata 5T ≈12.9% | ≈12.9% | 21.3% | Sejajar | |
| ROA (TTM) | 4.6%rata-rata 5T ≈5.2% | ≈5.2% | 8.5% | Lemah | |
| ROE (TTM) | -206.3%rata-rata 5T ≈3123.7% | ≈3123.7% | 22.1% | Tingkat teratas | |
| ROIC | -1254.6%rata-rata 5T ≈-129.2% | ≈-129.2% | 9.3% | Lemah |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | ABBV | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Utang / Ekuitas (MRQ) | -0.0rata-rata 5T ≈-0.2 | ≈-0.2 | 0.1 | Utang rendah | |
| Rasio Lancar (MRQ) | 0.8rata-rata 5T ≈0.8 | ≈0.8 | 2.3 | Likuiditas rendah | |
| Quick Ratio (Rasio Cepat) | 0.4rata-rata 5T ≈0.5 | ≈0.5 | 0.8 | Likuiditas rendah | |
| Interest Coverage (Cakupan Bunga) | 5.2rata-rata 5T ≈5.9 | ≈5.9 | 6.6 | Likuiditas rendah |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | ABBV | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 8.6%rata-rata 5T ≈6.4% | ≈6.4% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | 1.8%rata-rata 5T ≈2.6% | ≈2.6% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 5.9% | · | · | · | |
| EPS YoY | -1.3%rata-rata 5T ≈13.5% | ≈13.5% | · | · | |
| Net Income YoY (Laba Bersih YoY) | -1.2%rata-rata 5T ≈16.1% | ≈16.1% | · | · | |
| EPS CAGR 3Y (CAGR EPS 3T) | -29.1%rata-rata 5T ≈-19.1% | ≈-19.1% | · | · | |
| EPS CAGR 5Y (CAGR EPS 5T) | -2.8% | · | · | · | |
| Net Income CAGR 3Y (CAGR Laba Bersih 3T) | -29.1%rata-rata 5T ≈-18.5% | ≈-18.5% | · | · | |
| Net Income CAGR 5Y (CAGR Laba Bersih 5T) | -1.8% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | ABBV | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.5rata-rata 5T ≈0.4 | ≈0.4 | 0.5 | Sejajar | |
| Inventory Turnover (Perputaran Persediaan) | 4.0rata-rata 5T ≈4.8 | ≈4.8 | 3.6 | Tingkat teratas | |
| Receivables Turnover (Perputaran Piutang) | 5.2rata-rata 5T ≈5.3 | ≈5.3 | 6.3 | Lemah | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$1.1M | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
Rasio Pembayaran Dividen275.8%
Pembayaran Tahunan≈$6.92
CAGR Dividen 5T≈6.8%
Rentetan Pertumbuhan≈11
| Tanggal ex-dividen | Jumlah | Mata Uang | Imbal Hasil |
|---|---|---|---|
| Okt 15, 2026 | $1,73 | USD | ≈2.4% |
| Jul 15, 2026 | $1,73 | USD | ≈2.8% |
| Apr 15, 2026 | $1,73 | USD | ≈3.2% |
| Jan 16, 2026 | $1,73 | USD | ≈3.1% |
| Okt 15, 2025 | $1,64 | USD | ≈2.9% |
| Jul 15, 2025 | $1,64 | USD | ≈3.5% |
| Apr 15, 2025 | $1,64 | USD | ≈3.6% |
| Jan 15, 2025 | $1,64 | USD | ≈3.7% |
| Okt 15, 2024 | $1,55 | USD | ≈3.2% |
| Jul 15, 2024 | $1,55 | USD | ≈3.6% |
| Apr 12, 2024 | $1,55 | USD | ≈3.7% |
| Jan 12, 2024 | $1,55 | USD | ≈3.7% |
| Okt 12, 2023 | $1,48 | USD | ≈4.0% |
| Jul 13, 2023 | $1,48 | USD | ≈4.4% |
| Apr 13, 2023 | $1,48 | USD | ≈3.6% |
| Jan 12, 2023 | $1,48 | USD | ≈3.8% |
| Okt 13, 2022 | $1,41 | USD | ≈3.9% |
| Jul 14, 2022 | $1,41 | USD | ≈3.7% |
| Apr 13, 2022 | $1,41 | USD | ≈3.4% |
| Jan 13, 2022 | $1,41 | USD | ≈4.0% |
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
0.75%
Laporan Berikutnya
Okt 29, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Jul 29, 2026 | $3.65 | $3.68 | -0.71% |
| 31 Maret 2026 | $2.65 | $2.65 | 0.18% | |
| 31 Des. 2025 | $2.71 | $2.71 | 0.17% | |
| 30 Sep. 2025 | $1.86 | $1.81 | 2.7% | |
| 30 Juni 2025 | $2.97 | $2.94 | 0.95% | |
| 31 Maret 2025 | $2.46 | $2.43 | 1.1% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Cost of Revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B | $15.39B | $7.44B | $7.72B | $7.04B | $5.83B | $4.50B | $4.43B | |
| SG&A Expense | $14.01B | $14.75B | $12.87B | $15.26B | $12.35B | $11.30B | $6.94B | $7.40B | $6.29B | $5.88B | $6.39B | $7.72B | |
| Operating Expenses | $46.09B | $47.20B | $41.56B | $39.94B | $38.27B | $34.44B | $20.28B | $26.37B | $18.67B | $16.30B | $15.32B | $16.55B | |
| Operating Income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.54B | $9.34B | $7.54B | $3.41B | |
| Interest Expense | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B | $1.35B | $1.15B | $1.05B | $719M | $429M | |
| Other Non-op | $-5.79B | $-3.24B | $-4.68B | $-2.45B | $-2.50B | $-5.61B | $-3.01B | $-18M | $-466M | $-188M | $-13M | $27M | |
| Pretax Income | $6.60B | $3.72B | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B | $5.20B | $7.73B | $7.88B | $6.64B | $2.37B | |
| Income Tax | $2.36B | $-570M | $1.38B | $1.63B | $1.44B | $-1.22B | $544M | $-490M | $2.42B | $1.93B | $1.50B | $595M | |
| Net Income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| EPS (Basic) | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 | $3.67 | $3.31 | $3.65 | $3.15 | $1.11 | |
| EPS (Diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 | |
| Shares (Basic) | 1,769,000,000 | 1,769,000,000 | 1,768,000,000 | 1,771,000,000 | 1,770,000,000 | 1,667,000,000 | 1,481,000,000 | 1,541,000,000 | 1,596,000,000 | 1,622,000,000 | 1,625,000,000 | 1,595,000,000 | |
| Shares (Diluted) | 1,773,000,000 | 1,773,000,000 | 1,773,000,000 | 1,778,000,000 | 1,777,000,000 | 1,673,000,000 | 1,484,000,000 | 1,546,000,000 | 1,603,000,000 | 1,631,000,000 | 1,637,000,000 | 1,610,000,000 | |
| EBITDA | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.59B | $9.38B | $7.54B | $3.41B |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B | $8.45B | $39.92B | $7.29B | $9.30B | $5.10B | $8.40B | $8.35B | |
| Short-term Investments | $28M | $31M | $2M | $28M | $84M | $30M | $0 | $772M | $486M | $1.32B | $8M | $26M | |
| Receivables | $12.59B | $10.92B | $11.15B | $11.25B | $9.98B | $8.82B | $5.43B | $5.38B | $5.09B | $4.76B | $4.73B | · | |
| Inventory | $4.95B | $4.18B | $4.10B | $3.58B | $3.13B | $3.31B | $1.81B | $1.60B | $1.60B | $1.44B | $1.72B | $1.12B | |
| Prepaid Expense | $6.29B | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $29.06B | $25.58B | $33.00B | $28.46B | $27.93B | $24.17B | $49.52B | $16.95B | $21.22B | $16.19B | $16.31B | $16.08B | |
| PP&E (Net) | $5.63B | $5.13B | $4.99B | $4.93B | $5.11B | $5.25B | $2.96B | $2.88B | $2.80B | $2.60B | $2.56B | $2.48B | |
| PP&E (Gross) | $13.53B | $12.27B | $11.63B | $10.99B | $10.73B | $10.86B | $8.19B | $8.40B | $8.07B | $7.53B | $7.33B | $7.11B | |
| Accum. Depreciation | $7.90B | $7.13B | $6.65B | $6.05B | $5.62B | $5.61B | $5.23B | $5.51B | $5.27B | $4.92B | $4.77B | $4.62B | |
| Goodwill | $35.64B | $34.96B | $32.29B | $32.16B | $32.38B | $33.12B | $15.60B | $15.66B | $15.79B | $15.42B | $13.17B | $5.86B | |
| Intangibles | $52.64B | $60.07B | $55.61B | $67.44B | $75.95B | $82.88B | $18.65B | $21.23B | $27.56B | $28.90B | $19.71B | $1.51B | |
| Other Non-current Assets | $10.72B | $9.14B | $8.51B | $5.57B | $4.88B | $4.85B | $2.29B | $1.21B | $1.33B | $1.21B | $1.15B | $1.48B | |
| Total Assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B | |
| Accounts Payable | $34.73B | $2.94B | $3.69B | $2.93B | $2.88B | $2.28B | $1.45B | $1.55B | $1.47B | $1.41B | $1.60B | $1.40B | |
| Short-term Debt | $2.50B | $0 | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Current Liabilities | $43.29B | $38.75B | $37.84B | $29.54B | $35.19B | $28.66B | $15.59B | $17.24B | $16.64B | $9.78B | $10.89B | $11.39B | |
| Capital Leases | $689M | $697M | $735M | $754M | $713M | $832M | · | · | · | · | · | · | |
| Deferred Tax | $2.39B | $2.58B | $1.95B | $2.19B | $3.01B | $3.65B | $1.13B | $1.07B | $2.49B | $6.89B | $5.28B | $159M | |
| Other Non-current Liabilities | $32.57B | $30.13B | $32.33B | $30.66B | $28.70B | $27.61B | $17.60B | $1.31B | $1.24B | $1.16B | $844M | $990M | |
| Long-term Debt | $64.50B | $66.84B | $59.24B | $63.13B | $75.96B | $84.95B | $67.23B | · | · | · | · | · | |
| Total Debt | $2.50B | · | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Retained Earnings | $-15.49B | $-7.90B | $-1.00B | $4.78B | $3.13B | $1.05B | $4.72B | $3.37B | $5.46B | $4.38B | $2.25B | $535M | |
| Treasury Stock | $9.15B | $8.20B | $6.53B | $4.59B | $3.14B | $2.26B | $24.50B | $24.11B | $11.92B | $10.85B | $8.84B | $972M | |
| AOCI | $-1.14B | $-1.93B | $-2.31B | $-2.20B | $-2.90B | $-3.12B | $-3.60B | $-2.48B | $-2.73B | $-2.59B | $-2.56B | $-2.03B | |
| Stockholders' Equity | $-3.27B | $3.33B | $10.36B | $17.25B | $15.41B | $13.08B | $-8.17B | $-8.45B | $5.10B | $4.64B | $3.94B | $1.74B | |
| Liabilities + Equity | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $955M | $911M | $747M | $671M | $692M | $753M | $430M | $421M | $365M | $353M | $282M | $241M | |
| Deferred Tax | $-492M | $-1.45B | $-2.89B | $-1.93B | $-898M | $-2.33B | $122M | $-1.52B | $-4.16B | $-796M | $152M | $-380M | |
| Amort. of Intangibles | $7.38B | $7.62B | $7.95B | $7.69B | $7.72B | $5.80B | $1.55B | $1.29B | $1.08B | $764M | $419M | $403M | |
| Restructuring | · | · | · | · | · | · | $219M | $59M | $86M | $52M | $126M | $16M | |
| Operating Cash Flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B | $13.43B | $9.96B | $7.04B | $7.54B | $3.55B | |
| CapEx | $1.21B | $974M | $777M | $695M | $787M | $798M | $552M | $638M | $529M | $479M | $532M | $612M | |
| Investing Cash Flow | $-6.64B | $-20.82B | $-2.01B | $-623M | $-2.34B | $-37.56B | $596M | $-1.01B | $-274M | · | · | · | |
| Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Net Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Stock Repurchased | $980M | $1.71B | $1.97B | $1.49B | $934M | $978M | $629M | $12.01B | $1.41B | $6.03B | $7.59B | $665M | |
| Net Stock Activity | $-980M | $-1.71B | $-1.97B | $-1.49B | $-934M | $-978M | $-629M | $-12.01B | $-1.41B | $-6.03B | $-7.57B | $-652M | |
| Dividends Paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B | |
| Financing Cash Flow | $-12.72B | $-5.21B | $-17.22B | $-24.80B | $-19.04B | $-11.50B | $18.71B | $-14.40B | $-5.51B | $-3.93B | · | · | |
| Net Change in Cash | $-295M | $-7.29B | $3.61B | $-545M | $1.30B | $-31.48B | $32.63B | $-2.01B | $4.20B | $-3.30B | $51M | $-1.25B | |
| Taxes Paid | $3.63B | $4.10B | $4.70B | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B | $16.79B | $12.77B | $12.79B | $9.43B | $6.56B | $7.00B | $2.94B | |
| Levered FCF | $15.96B | $14.59B | $20.33B | $22.29B | $19.84B | $13.45B | $11.10B | $11.31B | $8.64B | $5.77B | $6.45B | $2.62B |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| Net Margin | 6.9% | 7.6% | 8.9% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% | · | · | |
| Pretax Margin | 10.8% | 6.6% | 11.5% | 23.2% | 23.1% | 7.4% | 25.3% | 15.9% | 27.4% | 30.8% | 29.1% | 11.9% | |
| EBITDA Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| ROA | 3.1% | 3.2% | 3.6% | 8.3% | 7.8% | 3.9% | 10.6% | 8.7% | 7.8% | 10.0% | · | · | |
| ROE | 15367.3% | 62.5% | 35.2% | 72.5% | 81.0% | 188.2% | -94.2% | -100.1% | 109.1% | 138.8% | · | · | |
| ROIC | -1254.6% | 317.0% | 96.0% | 92.3% | 103.3% | 117.9% | -148.6% | -147.1% | 119.9% | 141.3% | 134.1% | 117.9% |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 | 0.8 | 3.2 | 1.0 | 1.3 | 1.7 | 1.5 | 1.4 | |
| Quick Ratio | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 | 0.6 | 2.9 | 0.8 | 0.6 | 0.7 | 0.8 | 0.7 | |
| Debt / Equity | -0.8 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.4 | 0.1 | 0.1 | 0.1 | 0.2 | |
| Interest Coverage | 5.2 | 3.3 | 5.7 | 8.1 | 7.4 | 4.6 | 7.3 | 4.7 | 8.3 | 9.0 | 10.5 | 8.0 |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.6 | 0.7 | |
| Inventory Turnover | 4.0 | 4.1 | 5.3 | 5.2 | 5.4 | 6.0 | 4.4 | 4.8 | 4.6 | 3.7 | 3.2 | 3.9 | |
| Receivables Turnover | 5.2 | 5.1 | 4.8 | 5.5 | 6.0 | 6.4 | 6.2 | 6.3 | · | · | · | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $34.50 | $31.77 | $30.64 | $32.65 | $31.62 | $27.38 | $22.42 | $21.19 | $17.60 | $15.72 | $13.96 | $12.40 | |
| Cash Flow / Share | $10.73 | $10.61 | $12.88 | $14.03 | $12.82 | $10.51 | $8.98 | $8.69 | $6.21 | $4.32 | $4.60 | $2.20 | |
| Dividend / Share | $6.65 | $6.29 | $5.99 | $5.71 | $5.31 | $4.84 | $4.39 | $3.95 | $2.63 | $2.35 | $2.10 | $1.75 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | $3.95 | $2.63 | $2.35 | · | · | |
| EPS (TTM) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.6% | 3.7% | -6.4% | 3.3% | 22.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.8% | 0.08% | 5.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -1.3% | -12.1% | -59.0% | 2.8% | 137.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -29.1% | -28.2% | 0.00% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -2.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -1.2% | -12.0% | -58.9% | 2.5% | 150.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -29.1% | -28.2% | 1.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -1.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 8.6% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Net Income TTM | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| P/E | 96.8 | 74.4 | 57.0 | 24.4 | 21.0 | 39.4 | 16.8 | 25.2 | 29.3 | 17.3 | 18.9 | 59.5 | |
| Earnings Yield | 1.0% | 1.3% | 1.8% | 4.1% | 4.8% | 2.5% | 6.0% | 4.0% | 3.4% | 5.8% | 5.3% | 1.7% | |
| Payout Ratio | 275.8% | 257.7% | 216.7% | 84.9% | 80.2% | 167.2% | 80.8% | 98.1% | 77.4% | 62.4% | · | · | |
| Annual Payout | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B | $14.46B | $14.46B | $12.31B | $14.30B | $13.93B | $13.87B | $12.22B | $15.12B | $14.81B | |
| Cost of Revenue | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | $4.00B | $4.40B | $4.21B | $4.20B | $4.09B | $5.70B | $6.49B | $4.24B | $3.99B | $4.17B | $5.02B | |
| Gross Profit | · | · | $12.07B | · | · | · | $10.71B | · | · | · | $8.60B | · | · | · | $10.95B | · | |
| SG&A Expense | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | $3.29B | $3.85B | $4.21B | $3.38B | $3.31B | $3.19B | $3.37B | $3.27B | $3.04B | $3.42B | $3.30B | |
| Operating Expenses | $10.56B | $11.01B | $12.07B | $13.87B | $10.53B | $9.61B | $16.59B | $10.63B | $10.46B | $9.51B | $11.11B | $11.65B | $9.35B | $9.46B | $9.62B | $10.21B | |
| Operating Income | $6.43B | $3.99B | $4.54B | $1.90B | $4.89B | $3.73B | $-1.49B | $3.83B | $4.00B | $2.80B | $3.19B | $2.28B | $4.51B | $2.77B | $5.50B | $4.60B | |
| Interest Expense | $746M | $717M | $714M | $739M | $740M | $700M | $702M | $720M | $726M | $660M | $564M | $555M | $552M | $553M | $566M | $560M | |
| Interest Income | $67M | $72M | · | $72M | $62M | $73M | · | $129M | $220M | $207M | · | $157M | $98M | $99M | · | $63M | |
| Other Non-op | $-1.48B | $-2.31B | $-1.21B | $-503M | $-2.66B | $-1.45B | $-150M | $-1.16B | $-1.34B | $-586M | $-1.56B | $95M | $-1.41B | $-1.80B | $-2.02B | $330M | |
| Pretax Income | $4.28B | $1.04B | $2.67B | $714M | $1.55B | $1.66B | $-2.27B | $2.08B | $2.15B | $1.75B | $1.21B | $1.95B | $2.61B | $475M | $2.96B | $4.40B | |
| Income Tax | $662M | $342M | $853M | $526M | $613M | $372M | $-2.25B | $520M | $773M | $383M | $388M | $172M | $583M | $234M | $493M | $448M | |
| Net Income | $3.61B | $695M | $1.82B | $186M | $938M | $1.29B | $-22M | $1.56B | $1.37B | $1.37B | $822M | $1.78B | $2.02B | $239M | $2.47B | $3.95B | |
| EPS (Basic) | $2.04 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.02 | $0.88 | $0.77 | $0.77 | $0.46 | $1.00 | $1.14 | $0.13 | $1.39 | $2.22 | |
| EPS (Diluted) | $2.03 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.03 | $0.88 | $0.77 | $0.77 | $0.45 | $1.00 | $1.14 | $0.13 | $1.40 | $2.21 | |
| Shares (Basic) | 1,769,000,000 | 1,770,000,000 | · | 1,769,000,000 | 1,768,000,000 | 1,768,000,000 | · | 1,769,000,000 | 1,768,000,000 | 1,769,000,000 | · | 1,767,000,000 | 1,767,000,000 | 1,770,000,000 | · | 1,771,000,000 | |
| Shares (Diluted) | 1,771,000,000 | 1,774,000,000 | · | 1,772,000,000 | 1,771,000,000 | 1,772,000,000 | · | 1,772,000,000 | 1,771,000,000 | 1,773,000,000 | · | 1,771,000,000 | 1,771,000,000 | 1,776,000,000 | · | 1,776,000,000 | |
| EBITDA | $6.43B | $3.99B | · | $1.90B | $4.89B | $3.73B | · | $3.83B | $4.00B | $2.80B | · | $2.28B | $4.51B | $2.77B | · | $4.60B |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B | $5.52B | $7.26B | $13.13B | $18.07B | · | $13.29B | $8.76B | $6.71B | · | $11.83B | |
| Short-term Investments | · | · | $28M | $42M | $0 | $1M | $31M | $28M | $27M | $2M | · | $3M | $7M | $11M | · | $47M | |
| Receivables | $13.82B | $12.48B | $12.59B | $12.77B | $12.64B | $12.48B | $10.92B | $11.47B | $11.72B | $11.95B | · | $11.41B | $11.49B | $11.47B | · | $10.74B | |
| Inventory | $5.13B | $5.05B | $4.95B | $4.94B | $4.96B | $4.53B | $4.18B | $4.45B | $4.22B | $4.25B | · | $3.98B | $4.05B | $3.83B | · | $3.17B | |
| Prepaid Expense | $8.15B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $33.67B | $33.53B | $29.06B | $28.54B | $29.26B | $27.68B | $25.58B | $27.79B | $33.82B | $38.87B | · | $33.22B | $28.85B | $26.49B | · | $30.36B | |
| PP&E (Net) | $5.80B | $5.69B | $5.63B | $5.48B | $5.28B | $5.24B | $5.13B | $5.14B | $5.02B | $4.98B | · | $4.93B | $4.94B | $4.93B | · | $4.89B | |
| PP&E (Gross) | $13.96B | $13.73B | $13.53B | $13.23B | $12.93B | $12.57B | $12.27B | $12.28B | $11.90B | $11.72B | · | $11.37B | $11.32B | $11.14B | · | $10.68B | |
| Accum. Depreciation | $8.16B | $8.04B | $7.90B | $7.75B | $7.65B | $7.33B | $7.13B | $7.14B | $6.88B | $6.75B | · | $6.44B | $6.38B | $6.21B | · | $5.79B | |
| Goodwill | $35.52B | $35.57B | $35.64B | $35.63B | $35.64B | $35.28B | $34.96B | $35.30B | $33.39B | $33.43B | $32.29B | $32.09B | $32.22B | $32.22B | $32.16B | $31.73B | |
| Intangibles | $49.14B | $50.87B | $52.64B | $54.31B | $57.03B | $58.49B | $60.07B | $66.65B | $60.24B | $62.23B | · | $58.60B | $62.86B | $64.85B | · | $68.72B | |
| Other Non-current Assets | $10.73B | $10.54B | $10.72B | $9.64B | $9.66B | $9.19B | $9.14B | $8.29B | $9.20B | $9.07B | · | $7.09B | $6.20B | $5.80B | · | $5.38B | |
| Total Assets | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B | |
| Accounts Payable | $33.30B | $33.77B | $3.59B | $33.62B | $32.24B | $31.04B | $2.94B | $30.49B | $29.33B | $31.33B | · | $29.66B | $27.04B | $24.79B | · | $23.50B | |
| Short-term Debt | $0 | $0 | $2.50B | $3.79B | $5.56B | $1.59B | $0 | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Current Liabilities | $41.64B | $42.10B | $43.29B | $39.39B | $39.77B | $36.40B | $38.75B | $43.06B | $41.91B | $41.52B | · | $34.77B | $32.24B | $27.59B | · | $32.71B | |
| Capital Leases | · | · | $689M | · | · | · | $697M | · | · | · | · | · | · | · | · | · | |
| Deferred Tax | $2.28B | $2.33B | $2.39B | $2.48B | $2.55B | $2.58B | $2.58B | $2.75B | $2.73B | $2.72B | · | $2.04B | $2.12B | $2.11B | · | $1.97B | |
| Other Non-current Liabilities | $34.60B | $34.11B | $32.57B | $31.66B | $32.04B | $31.19B | $30.13B | $33.03B | $32.43B | $32.78B | · | $31.64B | $32.29B | $32.25B | · | $30.21B | |
| Long-term Debt | · | · | $64.50B | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $0 | $0 | · | $3.79B | $5.56B | $1.59B | · | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Retained Earnings | $-17.33B | $-17.87B | $-15.49B | $-14.23B | $-11.50B | $-9.53B | $-7.90B | $-4.96B | $-3.77B | $-2.38B | · | $933M | $1.79B | $2.39B | · | $4.95B | |
| Treasury Stock | $10.62B | $10.61B | $9.15B | $9.14B | $9.15B | $9.14B | $8.20B | $7.85B | $7.84B | $7.83B | · | $6.53B | $6.53B | $6.52B | · | $4.59B | |
| AOCI | $-1.16B | $-1.15B | $-1.14B | $-1.57B | $-1.54B | $-1.74B | $-1.93B | $-2.33B | $-2.51B | $-2.45B | · | $-2.35B | $-2.25B | $-2.23B | · | $-3.44B | |
| Stockholders' Equity | $-5.93B | $-6.66B | $-3.27B | $-2.64B | $-183M | $1.42B | $3.33B | $6.03B | $6.78B | $8.01B | · | $12.09B | $12.87B | $13.27B | · | $15.99B | |
| Liabilities + Equity | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $166M | $444M | $157M | $209M | $179M | $410M | $164M | $181M | $218M | $348M | $125M | $130M | $179M | $313M | $132M | $126M | |
| Deferred Tax | $-195M | $137M | $-385M | $193M | $-272M | $-28M | $-767M | $-277M | $-16M | $-389M | $-1.39B | $-863M | $-368M | $-267M | $-516M | $-621M | |
| Amort. of Intangibles | $1.70B | $1.75B | $1.72B | $1.90B | $1.90B | $1.86B | $1.93B | $1.90B | $1.90B | $1.89B | $1.90B | $2.00B | $2.10B | $1.95B | $2.03B | $2.00B | |
| Operating Cash Flow | $3.44B | $3.83B | $5.22B | $7.02B | $5.15B | $1.64B | $7.05B | $5.45B | $2.27B | $4.04B | $4.75B | $7.57B | $6.32B | $4.19B | $7.43B | $7.60B | |
| CapEx | $322M | $265M | $329M | $381M | $269M | $235M | $291M | $249M | $241M | $193M | $205M | $219M | $178M | $175M | $213M | $177M | |
| Investing Cash Flow | $-1.20B | $-574M | $-1.46B | $-3.26B | $-1.18B | $-735M | $-1.87B | $-8.26B | $-1.10B | $-9.59B | $-800M | $-369M | $-341M | $-499M | $-448M | $1.29B | |
| Debt Issued | $0 | $7.99B | $0 | $0 | $0 | $3.99B | $2.00B | $0 | $0 | $14.96B | · | $0 | $0 | $0 | $0 | $0 | |
| Net Debt Issued | · | $7.99B | · | · | · | $3.99B | · | · | · | $14.96B | · | · | · | $0 | · | · | |
| Stock Repurchased | $9M | $1.49B | $3M | $4M | $12M | $961M | $358M | $17M | $9M | $1.32B | $3M | $4M | $10M | $1.96B | $4M | $4M | |
| Net Stock Activity | · | $-1.49B | · | · | · | $-961M | · | · | · | $-1.32B | · | · | · | $-1.96B | · | · | |
| Dividends Paid | $3.07B | $3.09B | $2.91B | $2.91B | $2.91B | $2.92B | $2.75B | $2.75B | $2.75B | $2.77B | $2.63B | $2.63B | $2.62B | $2.66B | $2.51B | $2.50B | |
| Financing Cash Flow | $-5.05B | $919M | $-4.17B | $-4.59B | $-2.71B | $-1.26B | $-6.86B | $-3.07B | $-6.10B | $10.82B | $-4.45B | $-2.66B | $-3.92B | $-6.19B | $-9.63B | $-5.52B | |
| Net Change in Cash | $-2.82B | $4.16B | $-400M | $-838M | $1.29B | $-349M | $-1.73B | $-5.87B | $-4.94B | $5.25B | $-473M | $4.53B | $2.05B | $-2.49B | $-2.63B | $3.31B | |
| Free Cash Flow | · | $3.56B | · | · | · | $1.40B | · | · | · | $3.85B | · | · | · | $4.02B | · | · | |
| Levered FCF | · | $3.08B | · | · | · | $857M | · | · | · | $3.33B | · | · | · | $3.74B | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| Net Margin | 21.3% | 4.6% | · | 1.2% | 6.1% | 9.6% | · | 10.8% | 9.5% | 11.1% | · | 12.8% | 14.6% | 2.0% | · | 26.7% | |
| Pretax Margin | 25.2% | 6.9% | · | 4.5% | 10.1% | 12.4% | · | 14.4% | 14.8% | 14.3% | · | 14.0% | 18.8% | 3.9% | · | 29.7% | |
| EBITDA Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| ROA | 2.6% | 0.51% | · | 0.13% | 0.67% | 0.90% | · | 1.1% | 0.99% | 0.97% | · | 1.3% | 1.5% | 0.17% | · | 2.7% | |
| ROE | -118.1% | -26.6% | · | 11.0% | 28.4% | 27.3% | · | 17.2% | 14.0% | 12.9% | · | 12.7% | 14.7% | 1.6% | · | 26.7% | |
| ROIC | -91.6% | -40.2% | · | 43.7% | 55.2% | 96.2% | · | 47.7% | 37.7% | 27.3% | · | 17.2% | 27.2% | 10.6% | · | 25.8% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 0.8 | · | 0.7 | 0.7 | 0.8 | · | 0.6 | 0.8 | 0.9 | · | 1.0 | 0.9 | 1.0 | · | 0.9 | |
| Quick Ratio | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.4 | 0.6 | 0.7 | · | 0.7 | 0.6 | 0.7 | · | 0.7 | |
| Debt / Equity | 0.0 | 0.0 | · | -1.4 | -30.4 | 1.1 | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Interest Coverage | 8.6 | 5.6 | · | 2.6 | 6.6 | 5.3 | · | 5.3 | 5.5 | 4.2 | · | 4.1 | 8.2 | 5.0 | · | 8.2 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.9 | 0.9 | · | 1.1 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.8 | 1.1 | 1.1 | · | 1.6 | |
| Receivables Turnover | 1.3 | 1.2 | · | 1.3 | 1.3 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.5 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $9.59 | $8.46 | · | $8.90 | $8.71 | $7.53 | · | $8.16 | $8.17 | $6.94 | · | $7.86 | $7.83 | $6.88 | · | $8.34 | |
| Cash Flow / Share | · | $2.16 | · | · | · | $0.92 | · | · | · | $2.28 | · | · | · | $2.36 | · | · | |
| Dividend / Share | $1.73 | $1.73 | $1.73 | $1.64 | $1.64 | $1.64 | $1.64 | $1.55 | $1.55 | $1.55 | $1.55 | $1.48 | $1.48 | $1.48 | $1.48 | $1.41 | |
| EPS (TTM) | $3.54 | $2.03 | · | $1.31 | $2.09 | $2.34 | · | $2.87 | $2.99 | $3.36 | · | $3.67 | $4.88 | $4.25 | · | $7.49 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $64.39B | $62.82B | · | $59.64B | $58.33B | $57.37B | · | $55.53B | $55.00B | $54.40B | · | $55.14B | $56.02B | $56.74B | · | $57.82B | |
| Net Income TTM | $6.31B | $3.63B | · | $2.39B | $3.76B | $4.20B | · | $5.12B | $5.34B | $5.99B | · | $6.51B | $8.69B | $7.58B | · | $13.41B | |
| P/E | 71.1 | 107.1 | · | 176.7 | 88.8 | 89.5 | · | 68.8 | 57.4 | 54.2 | · | 40.6 | 27.6 | 37.5 | · | 17.9 | |
| Earnings Yield | 1.4% | 0.93% | · | 0.57% | 1.1% | 1.1% | · | 1.5% | 1.7% | 1.8% | · | 2.5% | 3.6% | 2.7% | · | 5.6% | |
| Payout Ratio | · | 444.0% | · | · | · | 227.5% | · | · | · | 202.5% | · | · | · | 1113.4% | · | · | |
| Annual Payout | $11.98B | $11.82B | · | $11.50B | $11.34B | $11.18B | · | $10.90B | $10.78B | $10.65B | · | $10.42B | $10.30B | $10.18B | · | $9.85B |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Margin Operasi % | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% |
| Laba Bersih | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| EPS Dilusian | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utang / Ekuitas | -0.8 | · | 0.0 | 0.0 | 0.0 |
| Rasio Lancar | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 |
| Rasio Cepat | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B |
Pemilik institusional (13F) 4.539 pengaju · $373.4B total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
4.539
Nilai yang dipegang
$373.4B
Posisi baru
252
Posisi yang keluar
104
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 252 (+6 vs Kuartal sebelumnya) | 104 (-71 vs Kuartal sebelumnya) | 1.934 (+223 vs Kuartal sebelumnya) | 1.546 (-163 vs Kuartal sebelumnya) | +33.9M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| VANGUARD GROUP INC | $41.306.353.424 | 180.779.699 | 11,06% | Saham |
| BlackRock, Inc. | $37.617.263.993 | 149.488.412 | 10,07% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $29.038.274.101 | 115.396.098 | 7,78% | Saham |
| STATE STREET CORP | $20.784.645.667 | 82.596.748 | 5,57% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12.199.002.913 | 48.477.996 | 3,27% | Saham |
| JPMORGAN CHASE & CO | $12.171.988.269 | 47.862.796 | 3,26% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $11.805.227.357 | 46.998.433 | 3,16% | Saham |
| MORGAN STANLEY | $9.789.048.614 | 38.901.001 | 2,62% | Saham |
| Capital Research Global Investors | $7.574.798.407 | 30.101.551 | 2,03% | Saham |
| NORGES BANK | $6.430.543.942 | 25.554.538 | 1,72% | Saham |
| BANK OF AMERICA CORP /DE/ | $5.344.270.976 | 21.237.764 | 1,43% | Saham |
| FMR LLC | $5.227.515.471 | 20.773.786 | 1,40% | Saham |
| NORTHERN TRUST CORP | $5.173.327.604 | 20.558.447 | 1,39% | Saham |
| FRANKLIN RESOURCES INC | $5.013.985.356 | 19.925.232 | 1,34% | Saham |
| Capital World Investors | $4.826.436.854 | 19.178.966 | 1,29% | Saham |
| GOLDMAN SACHS GROUP INC | $4.099.625.714 | 16.291.630 | 1,10% | Saham |
| Capital International Investors | $3.936.357.038 | 15.638.631 | 1,05% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3.250.509.754 | 12.914.230 | 0,87% | Saham |
| Bank of New York Mellon Corp | $3.234.421.677 | 12.853.368 | 0,87% | Saham |
| UBS Group AG | $3.232.345.996 | 12.845.120 | 0,87% | Saham |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3.080.007.690 | 14.161.606 | 0,82% | Saham |
| Legal & General Group Plc | $2.905.952.066 | 11.548.053 | 0,78% | Saham |
| AMERIPRISE FINANCIAL INC | $2.900.213.433 | 11.519.507 | 0,78% | Saham |
| DEUTSCHE BANK AG\ | $2.710.904.889 | 10.772.949 | 0,73% | Saham |
| RAYMOND JAMES FINANCIAL INC | $2.619.612.537 | 10.410.159 | 0,70% | Saham |
| Amundi | $2.526.281.104 | 10.039.289 | 0,68% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $2.501.249.007 | 9.939.791 | 0,67% | Saham |
| Nuveen, LLC | $2.393.093.998 | 9.509.991 | 0,64% | Saham |
| Fisher Asset Management, LLC | $2.390.069.445 | 9.497.970 | 0,64% | Saham |
| WELLS FARGO & COMPANY/MN | $2.269.183.889 | 9.017.580 | 0,61% | Saham |
| ROYAL BANK OF CANADA | $2.054.341.000 | 8.163.806 | 0,55% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $1.821.124.683 | 7.236.861 | 0,49% | Saham |
| Invesco Ltd. | $1.790.363.623 | 7.114.782 | 0,48% | Saham |
| JANUS HENDERSON GROUP PLC | $1.507.338.150 | 6.931.036 | 0,40% | Saham |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $1.482.866.205 | 5.892.808 | 0,40% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $1.272.188.414 | 5.055.589 | 0,34% | Saham |
| BARCLAYS PLC | $1.262.104.191 | 5.015.515 | 0,34% | Saham |
| Swiss National Bank | $1.255.358.984 | 4.988.710 | 0,34% | Saham |
| ENVESTNET ASSET MANAGEMENT INC | $1.229.678.938 | 4.886.670 | 0,33% | Saham |
| NORDEA INVESTMENT MANAGEMENT AB | $1.208.014.926 | 4.805.342 | 0,32% | Saham |
| Boston Partners | $1.202.518.364 | 4.784.316 | 0,32% | Saham |
| FEDERATED HERMES, INC. | $1.122.678.971 | 4.461.449 | 0,30% | Saham |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $1.110.959.915 | 4.388.338 | 0,30% | Saham |
| Mitsubishi UFJ Asset Management Co., Ltd. | $1.092.298.708 | 4.340.720 | 0,29% | Saham |
| HSBC HOLDINGS PLC | $1.040.184.766 | 4.131.637 | 0,28% | Saham |
| LPL Financial LLC | $1.030.798.580 | 4.096.323 | 0,28% | Saham |
| National Pension Service | $1.008.968.950 | 4.009.573 | 0,27% | Saham |
| PNC Financial Services Group, Inc. | $1.008.433.649 | 4.007.446 | 0,27% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.005.413.025 | 3.995.442 | 0,27% | Saham |
| Sumitomo Mitsui Trust Group, Inc. | $992.857.195 | 3.945.546 | 0,27% | Saham |
Aktivis & pemilik 5%+ 1 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| AbbVie Inc. | 6 Okt. 2017 | · | Pengajuan awal | M&A / penjualan | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 39 orang dalam · 22 pejabat · 15 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Robert A. Michael | CHAIRMAN OF THE BOARD AND CEO | 27 Feb. 2026 F | 178.737 | 0 | 0 | $0 |
| Scott T Reents | EVP, CHIEF FINANCIAL OFFICER | 27 Feb. 2026 F | 38.777 | 0 | 0 | $0 |
| Nicholas Donoghoe | EVP, CHIEF BUS/STRAT OFFICER | 14 Agu 2026 M | 74.430 | 0 | 1 | $-8.177.500 |
| Perry C Siatis | EVP, GC AND SECRETARY | 2 Maret 2026 S | 4.619 | 0 | 4 | $-9.523.179 |
| Demetris D Crum | EVP, CHIEF HR OFFICER | 27 Feb. 2026 F | 7.914 | 0 | 0 | $0 |
| David Ryan Purdue | SVP, Controller | 27 Feb. 2026 F | 8.468 | 0 | 1 | $-1.221.519 |
| Roopal Thakkar | EVP, R&D and CSO | 27 Feb. 2026 F | 52.376 | 0 | 0 | $0 |
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | 27 Feb. 2026 F | 83.171 | 0 | 0 | $0 |
| Azita Saleki-Gerhardt | EVP, CHIEF OPERATIONS OFFICER | 27 Feb. 2026 F | 197.794 | 0 | 0 | $0 |
| Timothy J. Richmond | EVP, CHIEF HR OFFICER | 3 Maret 2025 S | 6.130 | 0 | 0 | $0 |
| Kevin K Buckbee | SVP, CONTROLLER | 28 Feb. 2025 F | 7.797 | 0 | 0 | $0 |
| Thomas J Hudson | SVP, CSO, GLOBAL RESEARCH | 28 Feb. 2024 F | 107.267 | 0 | 0 | $0 |
| Carrie C Strom | SVP & PRES GLOBAL ALLERG AESTH | 11 Mei 2023 F | 28.024 | 0 | 0 | $0 |
| Elaine K. Sorg | SVP, US COMMERCIAL OPERATIONS | 25 April 2023 M | 35.330 | 0 | 0 | $0 |
| Brian L Durkin | VP, CONTROLLER | 28 Feb. 2023 F | 33.149 | 0 | 0 | $0 |
| Michael Severino | Vice Chairman | 23 Mei 2022 M | 152.103 | 0 | 0 | $0 |
| Henry O Gosebruch | EVP, Chief Strategy Officer | 16 Mei 2022 M | 41.623 | 0 | 0 | $0 |
| Laura J Schumacher | Vice Chairman | 25 Feb. 2022 F | 248.002 | 0 | 0 | $0 |
| Carlos Alban | Vice Chairman | 16 Nov. 2020 M | 114.899 | 0 | 0 | $0 |
| William J Chase | EVP, Finance & Administration | 26 Juni 2019 P | 169.552 | 0 | 0 | $0 |
| Thomas A. Hurwich | VP, Controller | 28 Feb. 2017 F | 62.329 | 0 | 0 | $0 |
| John M. Leonard | SVP, Chief Scientific Officer | 15 Maret 2013 M | 107.320 | 0 | 0 | $0 |
| Susan E Quaggin | Direktur | 30 Sep. 2026 A | 3.643 | 0 | 0 | $0 |
| Edward J Rapp | Direktur | 30 Sep. 2026 A | 45.964 | 0 | 0 | $0 |
| Jennifer L. Davis | Direktur | 8 Mei 2026 A | 3.643 | 0 | 0 | $0 |
| Melody B Meyer | Direktur | 8 Mei 2026 A | 17.616 | 0 | 0 | $0 |
| William H.L. Burnside | Direktur | 8 Mei 2026 A | 28.076 | 0 | 0 | $0 |
| Brett J Hart | Direktur | 8 Mei 2026 A | 20.590 | 0 | 0 | $0 |
| Frederick H Waddell | Direktur | 8 Mei 2026 A | 30.076 | 0 | 0 | $0 |
| Thomas J Falk | Direktur | 8 Mei 2026 A | 2.321 | 0 | 0 | $0 |
| Roxanne S Austin | Direktur | 8 Mei 2026 A | 39.576 | 0 | 0 | $0 |
| Robert J Alpern | Direktur | 31 Maret 2026 A | 35.646 | 0 | 0 | $0 |
| Glenn F Tilton | Direktur | 9 Mei 2025 A | 51.564 | 0 | 0 | $0 |
| Richard A Gonzalez | Direktur | 31 Maret 2025 G | 386.479 | 0 | 0 | $0 |
| Edward M Liddy | Direktur | 31 Maret 2022 A | 26.683 | 0 | 0 | $0 |
| Roy S Roberts | Direktur | 8 Mei 2015 A | 27.486 | 0 | 0 | $0 |
| ABBOTT LABORATORIES | Pemilik 10% | 12 Des. 2012 J | 0 | 0 | 0 | $0 |
| Rebecca B Roberts | · | 8 Mei 2026 A | 14.846 | 0 | 0 | $0 |
| Thomas C Freyman | · | 8 Mei 2026 A | 127.869 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 209 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 7,85% | 2.838 NS | 31 Juli 2026 | N-PORT |
| IYH · iShares Trust | 7,27% | 1.036.373 SH | 11 Sep. 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 6,56% | 5.317.086 SH | 19 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 6,42% | 841.398 NS | 31 Juli 2026 | N-PORT |
| HDV · iShares Trust | 6,19% | 3.722.395 SH | 11 Sep. 2026 | Harian |
| PJP · Invesco Exchange-Traded Fund Trust | 5,88% | 115.924 SH | 23 Okt. 2026 | Harian |
| CURE · Direxion Shares ETF Trust | 5,08% | 34.766 NS | 31 Juli 2026 | N-PORT |
| IXJ · iShares Trust | 5,07% | 825.161 SH | 11 Sep. 2026 | Harian |
| FLAG · Global X Funds | 4,82% | 326 NS | 31 Juli 2026 | N-PORT |
| LCOW · Pacer Funds Trust | 4,75% | 4.895 NS | 31 Juli 2026 | N-PORT |
| FDV · Federated Hermes ETF Trust | 3,29% | 115.545 NS | 31 Juli 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 3,25% | 524 NS | 31 Juli 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 3,09% | 5.079 NS | 31 Juli 2026 | N-PORT |
| QDEF · FlexShares Trust | 3,03% | 65.928 NS | 31 Juli 2026 | N-PORT |
| DGRO · iShares Trust | 3,02% | 5.092.684 SH | 11 Sep. 2026 | Harian |
| QDF · FlexShares Trust | 2,94% | 259.882 NS | 31 Juli 2026 | N-PORT |
| SNPV · DBX ETF Trust | 2,88% | 30.853 NS | 31 Agu 2026 | N-PORT |
| ABFL · Abacus FCF ETF Trust | 2,85% | 59.784 NS | 31 Juli 2026 | N-PORT |
| PAYR · Federated Hermes ETF Trust | 2,78% | 6.332 NS | 31 Juli 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,72% | 526 NS | 31 Juli 2026 | N-PORT |
| XT · iShares Trust | 2,45% | 373.158 SH | 11 Sep. 2026 | Harian |
| QLV · FlexShares Trust | 2,43% | 15.876 NS | 31 Juli 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 2,14% | 4.283 NS | 31 Juli 2026 | N-PORT |
| MGV · VANGUARD WORLD FUND | 2,10% | 1.110.490 SH | 19 Agu 2026 | Harian |
| FDIV · EA Series Trust | 2,08% | 4.854 NS | 31 Juli 2026 | N-PORT |
| ACVU · Hartford Funds Exchange-Traded Trust | 2,02% | 14.545 NS | 31 Juli 2026 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 2,02% | 60.734.000 | 23 Okt. 2026 | Harian |
| VIG · VANGUARD SPECIALIZED FUNDS | 1,94% | 9.981.469 SH | 19 Agu 2026 | Harian |
| NULV · Nushares ETF Trust | 1,89% | 165.856 NS | 31 Juli 2026 | N-PORT |
| VYM · VANGUARD WHITEHALL FUNDS | 1,85% | 7.067.444 SH | 19 Agu 2026 | Harian |
| DIVB · iShares Trust | 1,79% | 142.660 SH | 11 Sep. 2026 | Harian |
| PFM · Invesco Exchange-Traded Fund Trust | 1,78% | 50.079 SH | 23 Okt. 2026 | Harian |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,74% | 58.678 SH | 23 Okt. 2026 | Harian |
| FTLS · First Trust Exchange-Traded Fund III | 1,74% | 172.391 NS | 31 Juli 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 1,69% | 54.073.000 | 23 Okt. 2026 | Harian |
| VTV · VANGUARD INDEX FUNDS | 1,66% | 16.798.484 SH | 19 Agu 2026 | Harian |
| WCAP · Spinnaker ETF Series | 1,64% | 3.990 NS | 31 Juli 2026 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1,62% | 228.681 NS | 31 Juli 2026 | N-PORT |
| ALRG · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 1,59% | 532 NS | 31 Juli 2026 | N-PORT |
| SNPG · DBX ETF Trust | 1,58% | 878 NS | 31 Agu 2026 | N-PORT |
| JDIV · J.P. Morgan Exchange-Traded Fund Tr… | 1,58% | 811 NS | 31 Juli 2026 | N-PORT |
| OEI · Listed Funds Trust | 1,55% | 2.864 NS | 31 Juli 2026 | N-PORT |
| IWX · iShares Trust | 1,54% | 235.248 SH | 11 Sep. 2026 | Harian |
| EVUS · iShares Trust | 1,49% | 22.181 SH | 11 Sep. 2026 | Harian |
| VUS · Virtus ETF Trust II | 1,48% | 1.056 NS | 31 Juli 2026 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 1,41% | 5.472 NS | 31 Juli 2026 | N-PORT |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 1,40% | 370.528 NS | 31 Juli 2026 | N-PORT |
| FDRR · FIDELITY COVINGTON TRUST | 1,39% | 40.713 NS | 31 Juli 2026 | N-PORT |
| SNPD · DBX ETF Trust | 1,38% | 165 NS | 31 Agu 2026 | N-PORT |
| FLRG · FIDELITY COVINGTON TRUST | 1,37% | 15.882 NS | 31 Juli 2026 | N-PORT |
| CHRI · Global X Funds | 1,35% | 430 NS | 31 Juli 2026 | N-PORT |
| ILCV · iShares Trust | 1,31% | 68.754 SH | 11 Sep. 2026 | Harian |
| INFO · Harbor ETF Trust | 1,29% | 43.209 NS | 31 Juli 2026 | N-PORT |
| NULC · Nushares ETF Trust | 1,28% | 3.602 NS | 31 Juli 2026 | N-PORT |
| DSI · iShares Trust | 1,28% | 270.036 SH | 11 Sep. 2026 | Harian |
| JQUA · J.P. Morgan Exchange-Traded Fund Tr… | 1,24% | 407.751 NS | 31 Juli 2026 | N-PORT |
| XLG · Invesco Exchange-Traded Fund Trust | 1,22% | 499.671 SH | 23 Okt. 2026 | Harian |
| FDLO · FIDELITY COVINGTON TRUST | 1,16% | 65.557 NS | 31 Juli 2026 | N-PORT |
| BKDV · BNY Mellon ETF Trust II | 1,15% | 84.302 NS | 31 Juli 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 1,15% | 983.559 SH | 19 Agu 2026 | Harian |
| FQAL · FIDELITY COVINGTON TRUST | 1,14% | 64.248 NS | 31 Juli 2026 | N-PORT |
| DIVD · EA Series Trust | 1,14% | 976 NS | 31 Juli 2026 | N-PORT |
| FVAL · FIDELITY COVINGTON TRUST | 1,14% | 60.255 NS | 31 Juli 2026 | N-PORT |
| EQWL · Invesco Exchange-Traded Fund Trust | 1,13% | 112.675 SH | 23 Okt. 2026 | Harian |
| IWD · iShares Trust | 1,12% | 3.620.451 SH | 11 Sep. 2026 | Harian |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 1,11% | 204.016 NS | 31 Juli 2026 | N-PORT |
| SNPE · DBX ETF Trust | 1,10% | 126.962 NS | 31 Agu 2026 | N-PORT |
| UPSD · ETF Series Solutions | 1,10% | 5.134 NS | 31 Juli 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 1,09% | 14.559 NS | 31 Juli 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 1,07% | 107.107 NS | 31 Juli 2026 | N-PORT |
| BIGY · Tidal Trust II | 1,07% | 2.325 NS | 31 Juli 2026 | N-PORT |
| MPLY · Strategy Shares | 1,06% | 674 NS | 31 Juli 2026 | N-PORT |
| HAPI · Harbor ETF Trust | 1,06% | 20.723 NS | 31 Juli 2026 | N-PORT |
| DUHP · Dimensional ETF Trust | 1,05% | 514.323 NS | 31 Juli 2026 | N-PORT |
| EGLE · Global X Funds | 1,03% | 90 NS | 31 Juli 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,99% | 8.650 NS | 31 Juli 2026 | N-PORT |
| ACVF · ETF Opportunities Trust | 0,96% | 5.854 NS | 31 Juli 2026 | N-PORT |
| OEF · iShares Trust | 0,94% | 746.937 SH | 11 Sep. 2026 | Harian |
| FHEQ · Fidelity Greenwood Street Trust | 0,89% | 33.045 NS | 31 Juli 2026 | N-PORT |
| FBUF · Fidelity Greenwood Street Trust | 0,88% | 836 NS | 31 Juli 2026 | N-PORT |
| LRGF · iShares Trust | 0,87% | 124.903 SH | 11 Sep. 2026 | Harian |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,86% | 30.469.000 | 23 Okt. 2026 | Harian |
| USCL · iShares Trust | 0,84% | 93.511 SH | 11 Sep. 2026 | Harian |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,84% | 35.205 NS | 31 Juli 2026 | N-PORT |
| MGC · VANGUARD WORLD FUND | 0,84% | 353.229 SH | 19 Agu 2026 | Harian |
| ACIO · ETF Series Solutions | 0,84% | 78.510 NS | 31 Juli 2026 | N-PORT |
| TOPC · iShares Trust | 0,84% | 1.075 SH | 11 Sep. 2026 | Harian |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,83% | 219.693 SH | 19 Agu 2026 | Harian |
| ADME · ETF Series Solutions | 0,82% | 9.586 NS | 31 Juli 2026 | N-PORT |
| IVE · iShares Trust | 0,82% | 1.584.589 SH | 11 Sep. 2026 | Harian |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,81% | 133.875 SH | 23 Okt. 2026 | Harian |
| IWL · iShares Trust | 0,80% | 68.790 SH | 11 Sep. 2026 | Harian |
| VFMF · VANGUARD WELLINGTON FUND | 0,78% | 21.777 SH | 19 Agu 2026 | Harian |
| IUSV · iShares Trust | 0,77% | 834.812 SH | 11 Sep. 2026 | Harian |
| PBP · Invesco Exchange-Traded Fund Trust | 0,77% | 10.596 SH | 23 Okt. 2026 | Harian |
| XVV · iShares Trust | 0,77% | 20.330 SH | 11 Sep. 2026 | Harian |
| ESGU · iShares Trust | 0,77% | 537.992 SH | 11 Sep. 2026 | Harian |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,77% | 282.445 SH | 23 Okt. 2026 | Harian |
| LABU · Direxion Shares ETF Trust | 0,76% | 15.001 NS | 31 Juli 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,76% | 400.307 SH | 19 Agu 2026 | Harian |
| USMV · iShares Trust | 0,73% | 678.129 SH | 11 Sep. 2026 | Harian |
| COWG · Pacer Funds Trust | 0,72% | 63.118 NS | 31 Juli 2026 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0,70% | 2.063.411 SH | 19 Agu 2026 | Harian |
| TOV · EA Series Trust | 0,70% | 7.329 NS | 31 Juli 2026 | N-PORT |
| GLOF · iShares Trust | 0,70% | 5.491 SH | 11 Sep. 2026 | Harian |
| XRMI · Global X Funds | 0,70% | 1.388 NS | 31 Juli 2026 | N-PORT |
| XYLD · Global X Funds | 0,70% | 89.923 NS | 31 Juli 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0,69% | 45.894.828 SH | 19 Agu 2026 | Harian |
| DFSU · Dimensional ETF Trust | 0,69% | 62.490 NS | 31 Juli 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0,69% | 89.516 NS | 31 Juli 2026 | N-PORT |
| XTR · Global X Funds | 0,69% | 132 NS | 31 Juli 2026 | N-PORT |
| XYLG · Global X Funds | 0,69% | 1.758 NS | 31 Juli 2026 | N-PORT |
| IVV · iShares Trust | 0,69% | 22.269.390 SH | 11 Sep. 2026 | Harian |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,69% | 243.537 NS | 31 Juli 2026 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0,68% | 149.142 NS | 31 Juli 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,68% | 29.872 NS | 31 Juli 2026 | N-PORT |
| XCLR · Global X Funds | 0,68% | 97 NS | 31 Juli 2026 | N-PORT |
| ILCB · iShares Trust | 0,68% | 34.315 SH | 11 Sep. 2026 | Harian |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,67% | 796 NS | 31 Juli 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,66% | 231.867 SH | 23 Okt. 2026 | Harian |
| VOXP · Advisors Series Trust | 0,65% | 150 NS | 31 Juli 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,65% | 22.908 SH | 23 Okt. 2026 | Harian |
| PHDG · Invesco Actively Managed Exchange-T… | 0,65% | 1.392 SH | 23 Okt. 2026 | Harian |
| IWB · iShares Trust | 0,64% | 1.225.591 SH | 11 Sep. 2026 | Harian |
| DFUS · Dimensional ETF Trust | 0,64% | 535.096 NS | 31 Juli 2026 | N-PORT |
| IYY · iShares Trust | 0,64% | 75.779 SH | 11 Sep. 2026 | Harian |
| RECS · Columbia ETF Trust I | 0,64% | 148.900 NS | 31 Juli 2026 | N-PORT |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,64% | 292.723 SH | 19 Agu 2026 | Harian |
| SPUU · Direxion Shares ETF Trust | 0,63% | 6.666 NS | 31 Juli 2026 | N-PORT |
| IIGD · Invesco Exchange-Traded Self-Indexe… | 0,63% | 159.000 | 23 Okt. 2026 | Harian |
| QDPL · Pacer Funds Trust | 0,63% | 42.547 NS | 31 Juli 2026 | N-PORT |
| ESG · FlexShares Trust | 0,62% | 3.270 NS | 31 Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,62% | 488.074 SH | 11 Sep. 2026 | Harian |
| ITOT · iShares Trust | 0,61% | 2.300.210 SH | 11 Sep. 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,61% | 56.099.820 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,61% | 149.086 SH | 19 Agu 2026 | Harian |
| APUE · Trust for Professional Managers | 0,61% | 58.813 NS | 31 Agu 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,60% | 17.034.000 | 23 Okt. 2026 | Harian |
| IVW · iShares Trust | 0,58% | 1.733.440 SH | 11 Sep. 2026 | Harian |
| VOOG · VANGUARD ADMIRAL FUNDS | 0,58% | 603.900 SH | 19 Agu 2026 | Harian |
| TILT · FlexShares Trust | 0,56% | 48.980 NS | 31 Juli 2026 | N-PORT |
| IUSG · iShares Trust | 0,55% | 715.585 SH | 11 Sep. 2026 | Harian |
| DCOR · Dimensional ETF Trust | 0,55% | 73.443 NS | 31 Juli 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,55% | 12.296 NS | 31 Juli 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,54% | 18.022 SH | 19 Agu 2026 | Harian |
| WSGE · EA Series Trust | 0,54% | 1.303 NS | 31 Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,54% | 267.233 NS | 31 Juli 2026 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,53% | 704.000 | 23 Okt. 2026 | Harian |
| TOK · iShares Trust | 0,53% | 4.931 SH | 11 Sep. 2026 | Harian |
| RCGE · EA Series Trust | 0,53% | 2.130 NS | 31 Juli 2026 | N-PORT |
| KOKU · DBX ETF Trust | 0,52% | 16.567 NS | 31 Agu 2026 | N-PORT |
| PEVC · Pacer Funds Trust | 0,52% | 50 NS | 31 Juli 2026 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,52% | 23.445.000 | 22 Okt. 2026 | Harian |
| SPXL · Direxion Shares ETF Trust | 0,52% | 138.128 NS | 31 Juli 2026 | N-PORT |
| URTH · iShares, Inc. | 0,50% | 159.211 SH | 11 Sep. 2026 | Harian |
| VLLU · Harbor ETF Trust | 0,48% | 89 NS | 31 Juli 2026 | N-PORT |
| CRBN · iShares Trust | 0,48% | 21.813 SH | 11 Sep. 2026 | Harian |
| ACWV · iShares, Inc. | 0,47% | 61.945 SH | 11 Sep. 2026 | Harian |
| FDVV · FIDELITY COVINGTON TRUST | 0,45% | 183.861 NS | 31 Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,44% | 833.285 NS | 31 Juli 2026 | N-PORT |
| ACWI · iShares Trust | 0,44% | 563.215 SH | 11 Sep. 2026 | Harian |
| AFLG · First Trust Exchange-Traded Fund VI… | 0,42% | 12.525 NS | 31 Agu 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,42% | 114.618 NS | 31 Juli 2026 | N-PORT |
| DYNF · BlackRock ETF Trust | 0,41% | 664.980 SH | 11 Sep. 2026 | Harian |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,39% | 20.427 NS | 31 Juli 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,38% | 1.481.748 SH | 19 Agu 2026 | Harian |
| HDUS · Lattice Strategies Trust | 0,38% | 3.061 NS | 31 Juli 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,36% | 6.632 NS | 31 Juli 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,36% | 130.141 SH | 23 Okt. 2026 | Harian |
| DFVX · Dimensional ETF Trust | 0,35% | 7.418 NS | 31 Juli 2026 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0,30% | 9.382.000 | 23 Okt. 2026 | Harian |
| JFLI · J.P. Morgan Exchange-Traded Fund Tr… | 0,30% | 566 NS | 31 Juli 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 0,28% | 4.645 SH | 19 Agu 2026 | Harian |
| ROUS · Lattice Strategies Trust | 0,25% | 7.097 NS | 31 Juli 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,23% | 5.034 NS | 31 Juli 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 782.448 SH | 23 Okt. 2026 | Harian |
| PWS · Pacer Funds Trust | 0,21% | 205 NS | 31 Juli 2026 | N-PORT |
| SIZE · iShares Trust | 0,21% | 3.448 SH | 11 Sep. 2026 | Harian |
| QLC · FlexShares Trust | 0,20% | 8.064 NS | 31 Juli 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,20% | 14.673 SH | 11 Sep. 2026 | Harian |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,19% | 4.438 NS | 31 Juli 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,18% | 11.199 NS | 31 Juli 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,17% | 329 NS | 31 Juli 2026 | N-PORT |
| NPFE · Elevation Series Trust | 0,15% | 3.985 NS | 31 Juli 2026 | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0,15% | 193.000 | 23 Okt. 2026 | Harian |
| IWY · iShares Trust | 0,13% | 77.600 SH | 11 Sep. 2026 | Harian |
| PABU · iShares Trust | 0,11% | 10.895 SH | 11 Sep. 2026 | Harian |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0,11% | 223.700 SH | 19 Agu 2026 | Harian |
| IWF · iShares Trust | 0,11% | 530.953 SH | 11 Sep. 2026 | Harian |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 2.954 SH | 22 Okt. 2026 | Harian |
| SPXD · DBX ETF Trust | 0,08% | 21 NS | 31 Agu 2026 | N-PORT |
| ESMV · iShares Trust | 0,08% | 23 SH | 11 Sep. 2026 | Harian |
| NEAR · iShares U.S. ETF Trust | 0,05% | 2.690.000 SH | 11 Sep. 2026 | Harian |
| DEUS · DBX ETF Trust | 0,05% | 568 NS | 31 Agu 2026 | N-PORT |
| FEUS · FlexShares Trust | 0,02% | 110 NS | 31 Juli 2026 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 Juli 2026 | Harian |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 Juli 2026 | Harian |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 Juli 2026 | Harian |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 Juli 2026 | Harian |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | 15 Juli 2026 | Harian |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 Juli 2026 | Harian |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 Juli 2026 | Harian |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Juli 2026 | Harian |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Juli 2026 | Harian |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Juli 2026 | Harian |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 Juli 2026 | Harian |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 Juli 2026 | Harian |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | 15 Juli 2026 | Harian |
| VCEB · VANGUARD WORLD FUND | · | · | 30 Juli 2026 | Harian |
ABBV Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 39 analis
BELI
Target median
$286.50
+0,3%
10 25,6%
Beli Kuat
22 56,4%
Beli
7 17,9%
Tahan
0 0,0%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
28 analis · 2026-10-20Target rata-rata $282.61 -1,1%
Sekarang
Harga saat ini $285.64
Rendah$200.00
Rata-rata$282.61
Tinggi$328.00
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| ABBV | · | 96.8 | 8.6% | 6.9% | 15367.3% | · |
| AMGN | $176.35B | 23.0 | 10.0% | 21.0% | 95.9% | · |
| GILD | $152.32B | 18.1 | 2.4% | 28.9% | 40.5% | · |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | · |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | · |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | · |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | · |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
Nasdaq ·
Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?
Yahoo Finance ·
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
Nasdaq ·
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?
Nasdaq ·
AbbVie Sudah Jadi Raja Dividen, Ini Alasan Akuisisi Apogee Senilai $10,9 Miliar Bisa Ciptakan Dinasti
Nasdaq ·
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
Nasdaq ·
AbbVie (ABBV) to Acquire Apogee Therapeutics
Yahoo Finance ·
Is AbbVie a Buy After Its Purchase of Apogee?
Yahoo Finance ·
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
Yahoo Finance ·
AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
Yahoo Finance ·
Sinyal Perdagangan Sinyal beli/jual terbaru dengan harga masuk dan rasio risiko/imbalan
Tidak ada sinyal terbuka saat ini — tidak ada kartu yang terisi, dan itu jujur.
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 3, 2026